Influence of food on the pharmacokinetics of quinapril and its active diacid metabolite, CI-928. 1987

J J Ferry, and A M Horvath, and A J Sedman, and J R Latts, and W A Colburn
Warner-Lambert/Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan 48105.

A randomized two-way crossover study was conducted in 12 healthy volunteers to assess the effect of food on the pharmacokinetics of quinapril (CI-906) and its active metabolite, CI-928, after quinapril dosing. Forty-milligram oral quinapril doses were administered in a fasted or a fed state with a one-week washout period between treatments. No significant treatment differences were observed in quinapril and CI-928 values for maximum plasma concentration, area under the plasma concentration-time curve, or percentage of dose excreted in the urine. Small but significant increases of less than 0.5 hour in quinapril and CI-928 tmax values were observed after consumption of food. The pharmacokinetic profiles of quinapril and CI-928 were not significantly altered by the administration of food.

UI MeSH Term Description Entries
D007546 Isoquinolines A group of compounds with the heterocyclic ring structure of benzo(c)pyridine. The ring structure is characteristic of the group of opium alkaloids such as papaverine. (From Stedman, 25th ed)
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002849 Chromatography, Gas Fractionation of a vaporized sample as a consequence of partition between a mobile gaseous phase and a stationary phase held in a column. Two types are gas-solid chromatography, where the fixed phase is a solid, and gas-liquid, in which the stationary phase is a nonvolatile liquid supported on an inert solid matrix. Chromatography, Gas-Liquid,Gas Chromatography,Chromatographies, Gas,Chromatographies, Gas-Liquid,Chromatography, Gas Liquid,Gas Chromatographies,Gas-Liquid Chromatographies,Gas-Liquid Chromatography
D005502 Food Substances taken in by the body to provide nourishment. Foods
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077583 Quinapril A tetrahydroisoquinoline derivative and ANGIOTENSIN CONVERTING ENZYME inhibitor that is used in the treatment of HYPERTENSION and HEART FAILURE. 2-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid,Accupril,CI 906,CI-906,PD 109452-2,PD-109,452-2,Quinapril Hydrochloride,PD 109,452 2,PD 109452 2,PD 1094522
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000806 Angiotensin-Converting Enzyme Inhibitors A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. ACE Inhibitor,ACE Inhibitors,Angiotensin Converting Enzyme Inhibitor,Angiotensin I-Converting Enzyme Inhibitor,Angiotensin-Converting Enzyme Inhibitor,Kininase II Inhibitor,Kininase II Inhibitors,Angiotensin I-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Antagonists,Antagonists, Angiotensin-Converting Enzyme,Antagonists, Kininase II,Inhibitors, ACE,Inhibitors, Angiotensin-Converting Enzyme,Inhibitors, Kininase II,Kininase II Antagonists,Angiotensin Converting Enzyme Antagonists,Angiotensin Converting Enzyme Inhibitors,Angiotensin I Converting Enzyme Inhibitor,Angiotensin I Converting Enzyme Inhibitors,Antagonists, Angiotensin Converting Enzyme,Enzyme Antagonists, Angiotensin-Converting,Enzyme Inhibitor, Angiotensin-Converting,Enzyme Inhibitors, Angiotensin-Converting,II Inhibitor, Kininase,Inhibitor, ACE,Inhibitor, Angiotensin-Converting Enzyme,Inhibitor, Kininase II,Inhibitors, Angiotensin Converting Enzyme
D044005 Tetrahydroisoquinolines A group of ISOQUINOLINES in which the nitrogen containing ring is protonated. They derive from the non-enzymatic Pictet-Spengler condensation of CATECHOLAMINES with ALDEHYDES. Tetrahydro-Isoquinoline,1,2,3,4-Tetrahydroisoquinolines,Tetrahydro-Isoquinolines,Tetrahydro Isoquinoline,Tetrahydro Isoquinolines

Related Publications

J J Ferry, and A M Horvath, and A J Sedman, and J R Latts, and W A Colburn
October 1990, Journal of clinical pharmacology,
J J Ferry, and A M Horvath, and A J Sedman, and J R Latts, and W A Colburn
December 1990, Journal of clinical pharmacology,
J J Ferry, and A M Horvath, and A J Sedman, and J R Latts, and W A Colburn
April 1992, Journal of clinical pharmacology,
J J Ferry, and A M Horvath, and A J Sedman, and J R Latts, and W A Colburn
November 2009, British journal of clinical pharmacology,
J J Ferry, and A M Horvath, and A J Sedman, and J R Latts, and W A Colburn
January 1983, Drug-nutrient interactions,
J J Ferry, and A M Horvath, and A J Sedman, and J R Latts, and W A Colburn
March 2013, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association,
J J Ferry, and A M Horvath, and A J Sedman, and J R Latts, and W A Colburn
January 1993, Journal of pharmaceutical sciences,
J J Ferry, and A M Horvath, and A J Sedman, and J R Latts, and W A Colburn
October 2013, Xenobiotica; the fate of foreign compounds in biological systems,
J J Ferry, and A M Horvath, and A J Sedman, and J R Latts, and W A Colburn
May 2001, British journal of clinical pharmacology,
J J Ferry, and A M Horvath, and A J Sedman, and J R Latts, and W A Colburn
December 1988, Journal of clinical pharmacology,
Copied contents to your clipboard!